Oxbryta, the brand name for voxelotor, was once promoted as a major breakthrough for people living with sickle cell disease. In September 2024, Pfizer voluntarily withdrew Oxbryta from markets worldwide after new safety data raised serious concerns about vaso-occlusive crises and deaths in patients taking the drug. Pfizer stated that the “totality of clinical data” showed that Oxbryta’s benefits no longer outweighed its risks in the approved sickle cell patient population and cited “an imbalance in vaso-occlusive crises and fatal events.”

At TheLawFirm.com, we are providing this resource to help patients and families understand the serious potential health risks associated with this medication.

Why Was Oxbryta Recalled?

In September 2024, Pfizer issued a global recall of all lots of Oxbryta. Pfizer withdrew Oxbryta after reviewing clinical data that suggested “an imbalance in vaso-occlusive crises and fatal events,” meaning patients taking Oxbryta experienced more pain crises and deaths than patients in the placebo groups. 

European regulators identified two key studies that contributed to the recall. In the HOPE Kids 2 trial, data showed more deaths among children treated with Oxbryta than among children who received placebo. In another study, RESOLVE, regulators reported a higher-than-anticipated number of deaths. The European Medicines Agency ultimately concluded that Oxbryta’s benefits no longer outweighed its risks. 

Oxbryta was designed to help red blood cells carry more oxygen, but it potentially had the opposite effect for many, leading to:

• Vaso-Occlusive Crises (VOC): Blockages in blood vessels causing extreme, debilitating pain.
• Fatal Complications: A higher rate of death in clinical trial participants compared to those not taking the drug.
• Strokes & Vascular Events: Sudden blockages in the brain or major organs.
• Organ Damage: Progressive failure of the kidneys or liver due to lack of oxygen.

Oxbryta Litigation 

Filed Oxbryta complaints generally allege that Pfizer and Global Blood Therapeutics knew or should have known about serious safety risks associated with Oxbryta and failed to adequately warn patients, doctors, and regulators. The complaints focus on whether the manufacturers properly disclosed the risk of VOCs, fatal events, and other serious complications after safety signals emerged.

Potential causes of action may include:

• Strict liability, design defect: Plaintiffs may allege that Oxbryta was defectively designed because its risks outweighed its benefits for certain sickle cell patients.
• Strict liability, failure to warn: Plaintiffs may allege that Pfizer and Global Blood Therapeutics failed to provide adequate warnings about the risk of vaso-occlusive crises, fatal events, stroke, or other serious complications.
• Negligence: Plaintiffs may allege that the manufacturers failed to use reasonable care in designing, testing, monitoring, labeling, and marketing Oxbryta.
• Breach of express warranties: Plaintiffs may allege that the manufacturers made specific promises or representations about Oxbryta’s safety or benefits that the drug did not meet.
• Breach of implied warranties: Plaintiffs may allege that Oxbryta was not reasonably safe or fit for its intended use.
• Unjust enrichment: Plaintiffs may allege that Pfizer and Global Blood Therapeutics profited from Oxbryta while patients allegedly bore the risks of undisclosed safety concerns.
• False and misleading advertising: Plaintiffs may allege that Oxbryta was marketed in a false or misleading way, including through statements that overstated the drug’s benefits or understated its risks.
• Consumer protection violations: Depending on the state, plaintiffs may bring claims under consumer protection laws based on allegedly deceptive or unfair marketing practices.

Latest Update (May 2026): 

Oxbryta litigation is now developing on two tracks: individual injury claims and proposed class action claims. The individual lawsuits focus on patients who allege they suffered physical injuries after taking Oxbryta, including vaso-occlusive crises, stroke, hospitalization, or death. Those claims generally argue that Pfizer and Global Blood Therapeutics failed to adequately warn patients and physicians about serious safety risks associated with the drug.

A separate proposed class action is also pending in federal court in the Northern District of California. Unlike an individual injury case, the proposed class action focuses primarily on economic losses. The named plaintiffs allege that they paid money for Oxbryta and would not have done so if the manufacturers had fully disclosed the drug’s alleged safety risks. The proposed class seeks to represent people in the United States who purchased Oxbryta after November 2019 and were allegedly exposed to misleading safety-related marketing.

The proposed class action alleges that Pfizer and Global Blood Therapeutics continued selling and promoting Oxbryta despite safety concerns involving vaso-occlusive crises, infections, strokes, and deaths. It also alleges that the companies misrepresented the drug’s safety profile and failed to disclose information that would have affected patients’ decisions to buy or use the medication.

The litigation remains in an early stage. Pfizer has moved to dismiss the proposed class action, arguing that the plaintiffs have not pleaded enough facts to support their claims. The court has entered a schedule that includes class certification briefing, dispositive motion deadlines, and a trial date in August 2027 if the case proceeds and does not resolve before then.

Patients and families should understand the difference between these types of cases. A proposed class action may seek reimbursement or other economic damages for purchasers, while an individual personal injury lawsuit may seek compensation for physical injuries, medical bills, pain and suffering, hospitalization, stroke, organ damage, or wrongful death.

Do You Qualify for a Claim?

If you or a loved one were prescribed Oxbryta and suffered a significant medical complication, you may have a potential Oxbryta claim.  Every case depends on the patient’s prescription history, medical records, timing of the injury, and state law.

To pursue a potential Oxbryta claim, you will need: 

• Proof of Oxbryta use: Medical or pharmacy records showing that the patient was prescribed and used Oxbryta for at least six months prior to the 2024 market withdrawal.
• Proof of serious complication while taking Oxbryta: A diagnosis of a vaso-occlusive crisis requiring emergency treatment or hospitalization, stroke, organ injury, worsening sickle cell complications, or another serious medical event that occurred while taking the drug. 

Wrongful Death Claims Involving Oxbryta 

Families may have a potential wrongful death claim if a loved one died while taking Oxbryta or after suffering serious complications during Oxbryta treatment. These claims may involve allegations that Oxbryta contributed to fatal vaso-occlusive crises, stroke, organ failure, or other complications.

Wrongful death claims are governed by state law, and the rules vary by state. Depending on the state, the right to bring a claim may belong to a surviving spouse, children, parents, estate representative, or another legally authorized person. In some cases, families may need to take additional steps before a lawsuit can be filed, such as opening an estate, having a personal representative appointed, or obtaining other legal authority to bring the claim on behalf of the deceased person.